Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

BACKGROUND: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Public Health
Main Authors: Sodré, Sávio Lima, Barbosa, Italo Antunes França, Pacheco, Israel Emiliano, Ferreira, Felipe de Queiroz Tavares, David, Milton Agrizzi, Nascimento, Mauricio Abujamra, Arieta, Carlos Eduardo Leite, Vasconcellos, Jose Paulo Cabral de
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6740002/
https://ncbi.nlm.nih.gov/pubmed/31510981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12889-019-7562-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados